<DOC>
	<DOCNO>NCT01235572</DOCNO>
	<brief_summary>This phase II trial study well early discharge outpatient care work patient myelodysplastic syndrome acute myeloid leukemia previously treat intensive chemotherapy . Gathering information patient myelodysplastic syndrome acute myeloid leukemia discharge finish chemotherapy , stay hospital blood count return normal , may help doctor learn safety allow patient leave hospital early , patient 's quality life , use medical service , cost service associate policy .</brief_summary>
	<brief_title>Early Discharge Outpatients Care Patients With Myelodysplastic Syndrome Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Estimate early death rate patient discharge completion intensive induction salvage chemotherapy . SECONDARY OBJECTIVES : I . Compare cost incurred patient discharge early induction salvage chemotherapy similar patient discharge blood count recover . II . Compare resource utilization ( transfusion , etc . ) patient discharge early induction salvage chemotherapy similar patient discharge blood count recovery . III . Compare quality life patient discharge early induction salvage chemotherapy similar patient discharge blood count recover . OUTLINE : Patients discharge within 72 hour completion chemotherapy undergo standard outpatient care register nurse ( RN ) , physician assistant ( PA ) , resident/fellow local facility study center approximately 3 time per week , clinically indicate 45 day . After completion study , patient follow 1 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<criteria>Diagnosis myelodysplastic syndrome ( MDS ) acute myeloid leukemia ( AML ) acute promyelocytic leukemia ( APL ) ( 15 ; 17 ) ( q22 ; q12 ) , ( promyelocytic leukemia [ PML ] /retinoic acid receptor [ RAR ] ) , variant accord 2008 World Health Organization ( WHO ) classification Currently undergo AMLlike intensive induction reinduction chemotherapy , plan start therapy within 1 week Provide sign write informed consent Patients repeatedly enrol protocol ( e.g . induction 1st subsequent salvage therapy ) Drug hypersensitivity allergy disable use prophylactic antimicrobial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Acute myeloid leukemia multilineage dysplasia follow myelodysplastic syndrome</keyword>
	<keyword>Adult acute eosinophilic leukemia</keyword>
	<keyword>Adult acute basophilic leukemia</keyword>
	<keyword>De</keyword>
	<keyword>novo myelodysplastic syndrome</keyword>
	<keyword>Secondary myelodysplastic syndrome</keyword>
	<keyword>Untreated adult acute myeloid leukemia</keyword>
</DOC>